Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants
A prophylaxis strategy against RSV infection targeting all infants with nirsevimab could represent a cost-effective option for both NHS and societal perspectives, and supports the implementation and the equity of RSV prevention for all infants.
Authors
- Chiara Bini (ORCID: https://orcid.org/0000-0001-5704-6542)
- Daniele Cazzato (ORCID: https://orcid.org/0000-0002-7580-1422)
- Sabrine Soudani (ORCID: https://orcid.org/0000-0002-5731-3572)
- Eugenio Baraldi (ORCID: https://orcid.org/0000-0002-1829-3652)
- Luigi Orfeo
- Sara Boccalini (ORCID: https://orcid.org/0000-0002-9695-7549)
- Andrea Marcellusi (ORCID: https://orcid.org/0000-0002-3974-3798)
- Elena Bozzola (ORCID: https://orcid.org/0000-0003-2586-019X)
- Fabio Midulla (ORCID: https://orcid.org/0000-0001-7476-5266)
- Paolo Bonanni (ORCID: https://orcid.org/0000-0003-2875-3744)
- Barbara Muzii
Institutions
- University of Rome Tor Vergata (IT)
- University of Padua (IT)
- University of Milan (IT)
- Agostino Gemelli University Polyclinic (IT)
- Sanofi (France) (FR)
- Sanofi (Italy) (IT)
- Bambino Gesù Children's Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Florence (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2025-05-03
- DOI
- https://doi.org/10.1007/s40261-025-01437-8
- Citations
- 3
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- AstraZeneca
- Sanofi
- Università degli Studi di Roma Tor Vergata